Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal Cancer

Key Points Question Is disease progression associated with health-related quality of life among patients with cancer? Findings In this cohort study, mixed-model analyses of more than 8000 questionnaires from 2314 patients with metastatic breast, pancreatic, lung, or colorectal cancer showed that disease progression was accompanied by statistically significant and clinically relevant deterioration in many health-related quality-of-life scales. Meaning These findings suggest that time to progression and progression-free survival are important additional patient-relevant end points in the early benefit assessment of treatment for advanced cancer.

[1]  W. Vach,et al.  Development and validation of a novel prognostic score to predict survival in patients with metastatic colorectal cancer: the metastatic colorectal cancer score (mCCS) , 2019, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[2]  B. Gyawali,et al.  Association between progression‐free survival and patients’ quality of life in cancer clinical trials , 2018, International journal of cancer.

[3]  S. Hegewisch‐Becker,et al.  Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma , 2018, International journal of cancer.

[4]  G. Guyatt,et al.  Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analysis , 2018, JAMA internal medicine.

[5]  J. Ruof,et al.  Leveraging EUnetHTA’s conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer’s point of view , 2018, Health Economics Review.

[6]  L. Fallowfield,et al.  Do drugs offering only PFS maintain quality of life sufficiently from a patient’s perspective? Results from AVALPROFS (Assessing the ‘VALue’ to patients of PROgression Free Survival) study , 2018, Supportive Care in Cancer.

[7]  M. Lux,et al.  Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. , 2018, Breast.

[8]  P. Neven,et al.  Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  R. Schnell,et al.  Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort study. , 2017, Lung cancer.

[10]  L. Schwartzberg,et al.  Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study , 2017, Health and Quality of Life Outcomes.

[11]  H. Tesch,et al.  Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer - Results from the prospective German TMK cohort study. , 2017, Breast.

[12]  Tanya P. Garcia,et al.  Statistical Approaches to Longitudinal Data Analysis in Neurodegenerative Diseases: Huntington’s Disease as a Model , 2017, Current Neurology and Neuroscience Reports.

[13]  H. Leufkens,et al.  Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  G. Guyatt,et al.  Association between progression-free survival and health-related quality of life in oncology: a systematic review protocol , 2016, BMJ Open.

[15]  L. Fallowfield,et al.  Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits , 2016, Supportive Care in Cancer.

[16]  H. Kölsch,et al.  Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports , 2015, BMJ : British Medical Journal.

[17]  P. Fayers,et al.  Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib , 2014, BMJ Open.

[18]  E. Basch,et al.  Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life? , 2013 .

[19]  P. Fayers,et al.  Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. , 2012, European journal of cancer.

[20]  Alireza Atri,et al.  An Overview of Longitudinal Data Analysis Methods for Neurological Research , 2011, Dementia and Geriatric Cognitive Disorders Extra.

[21]  E. Stepanski,et al.  Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients , 2011, Health and quality of life outcomes.

[22]  Bing Li,et al.  Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. , 2011, American journal of epidemiology.

[23]  S. Johnston,et al.  Quality of Life in Hormone Receptor–Positive HER-2+ Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib , 2010, The oncologist.

[24]  J. Coebergh,et al.  The impact of disease progression on perceived health status and quality of life of long-term cancer survivors , 2009, Journal of cancer survivorship : research and practice.

[25]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.

[26]  G. Guyatt,et al.  The clinical significance of quality of life assessments in oncology: a summary for clinicians , 2006, Supportive Care in Cancer.

[27]  P. Fayers,et al.  The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. , 2006, European journal of cancer.

[28]  R. Stephens.  The Analysis, Interpretation, and Presentation of Quality of Life Data , 2004, Journal of biopharmaceutical statistics.

[29]  R C Littell,et al.  Mixed Models: Modelling Covariance Structure in the Analysis of Repeated Measures Data , 2005 .

[30]  C. Moinpour,et al.  Challenges posed by non‐random missing quality of life data in an advanced‐stage colorectal cancer clinical trial , 2000, Psycho-oncology.

[31]  D. Osoba,et al.  Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[33]  D. Tulsky,et al.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  G. Huston.  The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.

[35]  W. Copeman.  Clinical Epidemiology , 1948, Proceedings of the Royal Society of Medicine.